Monday, Sep 8, 2025 · SEC filings
What the smart money revealed on Sep 8
419 insider filings came in. We hid 69 planned (10b5-1) sellers and 218 people whose filings were routine, like grants and tax withholding.
Mineralys Therapeutics (MLYS) Director Srinivas Akkaraju bought $15M
588,235 shares on the open market. Not a grant or an option exercise. Their past buys: 3 of 7 checked quarters beat the typical stock 6 months later.
NovoCure (NVCR) CEO Ashley Cordova bought $997K
81,550 shares on the open market. Not a grant or an option exercise.
C1 Fund (CFND) Director Scott Reed bought $554K
60,000 shares on the open market. Not a grant or an option exercise.
Advanced Flower Capital (AFCG) Director Leonard Tannenbaum bought $363K
79,665 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 11 checked quarters beat the typical stock 6 months later.
American Express (AXP) Chairman and CEO Stephen Squeri sold $37M
Not marked as a planned 10b5-1 sale. Sold 55% of the shares they held directly. Still holds 92,810 shares.
Elastic N.V. (ESTC) CTO Shay Banon sold $17.1M
Not marked as a planned 10b5-1 sale. Sold 9% of the shares they held directly. Still holds 2.05M shares.
Perimeter Solutions (PRM) President - Global Fire Safety Jeffrey Emery sold $6.68M
Not marked as a planned 10b5-1 sale. Sold every share held directly.
Show 27 more real buys
Show 69 more real sales
13F season
Holdings as of Jun 30, 2025 were due Aug 14
74 funds have filed. 68 filed for the quarter before.
Biggest real insider buys, Sep 2–8
Open-market buys by officers and directors, filed in the 7 days up to Sep 8.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.